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ABSTRACT
Rifampin is one of first-line drugs for the treatment of tuberculosis. In Indonesia nearly all 
tuberculosis patients show lower rifampin plasma concentration’s possibly due to genetics. 
Rifampin is a substrate of the organic anion-transporting polypeptide 1B1 (OATP 1B1) 
encoded by the solute carrier organic anion transporter family member 1B1 (SLCO1B1). 
This study aimed to identify haplotype polymorphisms of tuberculosis drug transporters 
with an impact on clinical outcome in tuberculosis patients. Thirty-six patients from I.A 
Moeis District Hospital, Samarinda, East Kalimantan were involved in the study. Buffy 
coat from patient blood samples were tested for SLCO1B1 and SLCO1B3 polymorphisms 
by RFLP and ARMS PCR, whereas the clinical outcome was examined based on the 
sputum conversion histopathology residuals. The frequency of patients with SLCO1B1*15 
haplotype was 63.9%. The SLCO1B1*15 haplotype was associated with susceptibility to 
failure of clinical outcome (p=0.005; RR=4.52; 95% CI: 1.22-16.64). The OATP1B1*15 
haplotype revealed that the failure of clinical outcome was markedly increased compared 
to the three other haplotypes. These results suggest that the SLCO1B1*15 haplotype 
is an important predisposing factor for lower clinical outcome. Our data indicate that 
individualized treatment should be considered for Indonesian tuberculosis patients based 
on genetics characteristics of patients. 
ABSTRAK
Rifampin merupakan salah satu obat utama untuk pengobatan tuberkulosis. Di Indonesia 
hampir semua penderita tuberkulosis menunjukkan konsentrasi rifampisin yang rendah 
yang kemungkinan karena faktor genetik. Rifampin merupakan substrat dari Organic 
anion-transporting polypeptide 1B1 yang dikode oleh gen Solute carrier organic anion 
transporter family member 1B1 (SLCO1B1). Penelitian ini bertujuan mengidentifikasi 
polimorfisme haplotipe transporter obat tuberkulosis dan hubungannya dengan luaran 
klinis penderita tuberkulosis. Sebanyak 36 penderita tuberkulosis dari RSUD I.A. Moeis, 
Samarinda, Kalimantan Timur terlibat dalam penelitian. Buffy coat sampel darah pasien 
diperiksa polimorfisme SLCO1B1 dan SLCO1B3 menggunakan PCR RFLP dan ARMS, 
sedangkan luaran klinis ditentukan berdasarkan konversi sputum dan hasil histopatologi. 
Frekuensi penderita dengan SLCO1B1*15 haplotipe sebanyak 63,9%. SLCO1B1*15 
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haplotipe berhubungan dengan risiko kegagalan pengobatan hasil klinis (p=0,005; 
RR=4,52; 95% CI: 1,22-16,64). OATP1B1*15 haplotipe mengungkapkan bahwa 
kegagalan hasil klinis lebih tinggi dibandingkan ketiga haplotipe lainnya. Hasil penelitian ini 
terbukti SLCO1B1*15 haplotipe merupakan faktor predisposisi penting untuk memprediksi 
rendahnya luaran klinis. Disarankan agar pengobatan penderita tuberkulosis secara individu 
harus dipertimbangkan berdasarkan karakteristik genetik pasien.
Keyword:  SLCO1B1*15 haplotipe - tuberculosis - clinical outcome
INTRODUCTION
Tuberculosis (TB) is one of the major 
mortality risks in the world and is caused by 
Mycobacterium tuberculosis, which infects 
over 2 billion people, or almost one third of the 
world’s 7 billion population.1 Indonesia has 
the second ranked largest number of cases in 
the world. Rifampin (RIF) is a key component 
in the treatment regimen and due to its 
efficacy is used as a primary anti-TB drug.1,2 
The development of resistance to RIF is found 
to be related to RIF concentrations.3 Despite 
this concern, there is limited RIF dosing 
information to ensure optimal outcome. A 
number of studies have shown interindividual 
RIF pharmacokinetic variability4-6 and this 
genetic diversity may support the need 
to increase RIF dosage in Indonesian TB 
patients.7 Recent research has explored a link 
between genetics and treatment efficacy4,8 
and the present study is the first to assess 
genetic diversity in Indonesian patients with 
confirmed diagnosis of pulmonary TB (PTB) 
and extrapulmonary TB (EPTB). In evaluating 
clinical outcomes, we examined major 
single-nucleotide polymorphisms (SNPs) of 
SLCO1B1 and SLCO1B3. Considering genetic 
aspects potentially influential on the reduced 
levels of RIF concentration’s. 
As a substrate of organic anion transporting 
polypeptides OATP1B1 (coded by SLCO1B1) 
and OATP1B3 (coded by SLCO1B3),9,10 SNP 
research has associated the SLCO1B1 SNP 
C463A4 and rs41490328 with reduced RIF 
exposure. Other recent studies showed that it 
did not influence the exposure and involves 
genetic variability11,12 while presently there 
are no studies of the major SNPs in Indonesian 
patients. This study aimed to determine the 
major SNPs which may influence efficacy of 
treatment among Indonesian PTB and EPTB 
patients and the second objective of the study 
was to evaluate their potential impact on the 
clinical outcome. Applying our assessment of 
genetic variability to clinical outcomes, the 
data may assist in therapeutic-drug treatment 
schedules and monitoring in PTB and EPTB 
patients in Indonesia.
MATERIALS AND METHODS
Participants
This study used a cohort study, where 
we analyzed 36 patients with PTB and EPTB 
who had received an oral anti-TB regimen 
at I.A. Moeis District Hospital, Samarinda, 
Indonesia in 2014. The study participants 
had sputum smear-positive pulmonary TB or 
extrapulmonary TB from tissue biopsy which 
was definite if histopathology results showed 
the typical necrotizing granuloma containing 
macrophages, lymphocytes and Langhans 
giant cells. Caseous necrosis can be sometimes 
found in the central part of the granuloma, 
including: lymph node TB, gastrointestinal 
TB, skin and soft tissue TB. Directly observed 
daily administration of treatment involved 
J Med Sci, Volume 50, No. 1, 2018 January: 50-58
52
fixed-dose combination tablets (4FDC) 
with 150 mg rifampin, 75 mg isoniazid, 400 
mg pyrazinamide and 275 mg ethambutol. 
Following Indonesian standard tuberculosis 
treatment guidelines, patients < 38 kg 
received 2 tablets daily, those weighing 38 to 
54 kg received 3 tablets, 55 to 70 kg received 
4 tablets daily and patients > 71 kg received 
5 tablets once daily.13 All patients received 
TB drugs from the same manufacturer. The 
following variables were available: sex, age, 
BMI, ethnic and clinical outcome, including 
sputum smear and post-treatment biopsy. The 
study has been approved by the Medical and 
Health Research Ethics Committee, Faculty 
of Medicine, Public Health and Nursing 
Universitas Gadjah Mada, Yogyakarta. 
Genotyping 
We extracted blood sample DNA from the 
buffy coat by using the GeneJET Genomic 
DNA Purification Kit #K0722 (Thermo Fisher 
Scientific). We used the restriction fragment 
length polymorphism (RFLP) PCR for allelic 
discrimination in genotyping [SLCO1B1 
rs2306283 (c.388 A>G), SLCO1B1 
rs11045818 (c.411 G>A), SLCO1B3 
rs4149117 (c.334 T>G) and rs7311358 
(c.699 G>A)] and the amplification refractory 
mutation system (ARMS) PCR [SLCO1B1 
rs4149056 (c.521T>C)]. Primers were 
sourced from Integrated DNA Technologies 
(Coralville, Iowa, USA). Two samples of each 
genotype were directly sequenced to confirm 
and validate our genotyping results with 
Applied Biosystems 3730 DNA Analyzer. 
The protocol to prepare the PCR involved an 
initial denaturation step at 94°C for 5 to 7 min, 
followed by 35 to 40 cycles of denaturation 
at 94°C for 30 to 60 s and then annealing 
temperature for 30 to 60 s and extension 
at 72°C for 30 to 60 s (TABLE 1). All PCR 
amplifications were conducted in a PCR-
engine apparatus T100TM Thermal Cycler 
(Bio-Rad Life Science, USA). Restriction 
enzymes were sourced from Thermo Fisher 
Scientific. TABLE 1 below identifies the 
following SNPs based on allele frequencies 
previously shown to be involved in drug 
transport from the blood to the liver.
TABLE 1. Primers and PCR conditions used for genotyping of gene polymorphisms
Polymorphism Primer sequence (5’ 3’)a
Fragment 
size (bp)
Annealing 
temperature  
(ºC)
Amplification 
cycles
Restriction 
enzyme
SLCO1B1 
rs2306283 and 
rs11045818
F: GCAAATAAAGGGGAATATTTCTC 274 46 37 TaqI
R: AGAGATGTAATTAAATGTATAC
SLCO1B1 
rs4149056
F: AAGTAGTTAAATTTGTAATAGAAATGC 260 48 35 -
WT: GGGTCATACATGTGGATATAAGT
MT: AAGCATATTACCCATGAACG
R: GTAGACAAAGGGAAAGTGATCATA
SLCO1B3 
rs4149117
F: GAAGGTACAATGTCTTGGGC 339 58 35 AluI
R: CTCTCAAAAGGTAACTGCCC
SLCO1B3 
rs7311358
F: ATGATTACATTCCCTGGATC 303 56.3 40 RsaI
R: ACTATCATGGTACCTTGTTC
aF: Forward primer; R: reverse primer; WT: wild-type; MT: mutant-type
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For SLCO1B1 rs2306283 and rs11045818, 
the PCR product was digested using 5U of 
restriction enzyme at 65°C overnight. The 
products of restriction were placed in 3% 
agarose gel for electrophoresis and visualized 
by ethidium bromide staining. The restriction 
pattern consist of four distinct zones (154, 
142, 132 and 119 bp), each representative for 
388A>G and 411G>A wild-type and mutant 
alleles. This pattern in descending order 
stands for the two polymorphisms as follows: 
154 bp for 411A, 142 bp for 388A, 132 bp for 
411G and 119 bp for 388G.14
For SLCO1B1 rs4149056, the tetra 
primer used in ARMS-PCR with slight 
modifications.15 Because the restriction 
endonuclease was unnecessary, the PCR 
products were detected by means of 2% 
agarose gel with electrophoresis and by 
ethidium bromide staining. This pattern stands 
for the polymorphisms as follows: wild-type 
(260 and 179 bp); heterozygote (260, 123 and 
179 bp) and mutant (260 and 123 bp). For 
SLCO1B3 rs4149117, the PCR product was 
digested using 5U of restriction enzyme at 37°C 
overnight. The products of restriction were 
placed in 2% agarose gel for electrophoresis 
and visualized by ethidium bromide staining. 
The restriction pattern consists of two distinct 
zones (253 and 213 bp). This pattern stands 
for the polymorphisms as follows: wild-type 
(253 bp); heterozygote (253 and 213 bp) and 
mutant (213 bp).16
For SLCO1B3 rs7311358, the PCR product 
was digested using 5U of restriction enzyme. 
The restriction pattern consists of two distinct 
zones (242 and 275 bp). This pattern stands 
for the polymorphisms as follows: wild-type 
(242 bp); heterozygote (242 and 275 bp) and 
mutant (275 bp).16 In follow-up we assessed 
the clinical outcome with sputum conversion 
(PTB) or tissues through fine needle aspiration 
biopsy (EPTB). We compared the pre and 
post-treatment results. We categorized success 
if sputum conversion or lesions typically 
disappeared and improved histopathologically 
after the initiation of treatment. The failure of 
treatment outcome meant sputum conversion 
or lesions did not disappear and did not 
improve histopathologically. 
Statistical analysis
Data were presented as median or 
percentage. The association between genetics 
polymorphisms of SLCO and clinical outcome 
was analysed using Fisher’s exact test. A 
p-value <0.05 was considered as significant.
J Med Sci, Volume 50, No. 1, 2018 January: 50-58
54
RESULTS
Thirty-six tuberculosis patients including 
24 (66.7%) PTB and 12 (33.3%) EPTB were 
The two most common SLCO1B1 
SNPs (c.521T>C and c.388A>G) form four 
functionally distinct haplotypes: SLCO1B1*1a 
(c.388A-c.521T, as reference haplotype), *1b 
(c.388G-c.521T), *5 (c.388A-c.521C), and 
*15 (c.388G-c.521C).17-19 All polymorphisms 
were in Hardy-Weinberg equilibrium. The 
patients carrying at least one *15 haplotype 
had a significantly increased risk for failure of 
treatment (p=0.005), and subjects carrying the 
*15 haplotype had a 4.52-fold significantly 
elevated risk (95% CI: 1.22-16.64) for failure 
of treatment. The SLCO1B1 rs11045818 
was not analyzed due to its insignificance. 
The SLCO1B3 rs4149117 and rs7311358 
polymorphisms did not have a statistically 
significant association with clinical outcome. 
We evaluated the differences in the haplotype-
associated effects on clinical outcome, which 
also were associated with differences in 
overall drug exposures (TABLE 3). 
involved in this study. The demographics 
and genetics of the patients are presented in 
TABLE 2.
TABLE 2. Demographics and genotype description of cohort
Demographics
Median (range) or n (%)
Male 22 (61.11%) Female 14 (38.89%)
Age (years) 
Body weight (kg) 
Height (m) 
BMI (kg/m2)
42 (23-60) 
48 (37-65) 
1.56 (1.42-1.72) 
20.1 (16-27.7)
39 (16-65) 
46.5 (35-98) 
1.51 (1.4-1.63) 
21.4 (15.4-38.3)
Genetics Homozygous wild type, 
n (%)
Heterozygous mutant type, 
n (%)
Homozygous mutant type, 
n (%)
SLCO1B1 rs11045818 
SLCO1B1 rs2306283 
SLCO1B1 rs4149056 
SLCO1B3 rs4149117 
SLCO1B3 rs7311358
31 (86.11) 
0 (0) 
3 (8.33) 
2 (5.55) 
2 (5.55)
5 (13.89) 
10 (27.78) 
32 (88.89) 
14 (38.89) 
14 (38.89)
0 (0) 
26 (72.22) 
1 (2.78) 
20 (55.56) 
20 (55.56)
Haplotype n (%) Male, n (%) Female, n (%)
SLCO1B1 *1a 
SLCO1B1 *1b 
SLCO1B1 *5 
SLCO1B1 *15
9 (25) 
35 (97.2) 
8 (22.2) 
23 (63.9)
3 (13.6) 
22 (100) 
3 (13.6) 
11 (50)
6 (42.8) 
13 (92.3) 
5 (35.7) 
12 (85.7)
BMI: body mass index
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TABLE 3. Response treatment based on genotype of TB patients (n = 36)
Genetics Success 18 (50%)
Failure 
18 (50%) p
a RR (CI)b
SLCO1B1 rs11045818 
 GG 
 GA 
 AA
15 (41.7) 
3 (8.3) 
0 (0)
16 (44.4) 
2 (5.6) 
0 (0)
1 0.775 (0.25-2.39)
SLCO1B1 rs2306283 
 AA 
 AG 
 GG
0 (0) 
6 (16.7) 
12 (33.3)
0 (0) 
4 (11.1) 
14 (38.9)
0.711 -
SLCO1B1 rs4149056 
 TT 
 TC 
 CC
2 (5.5) 
15 (41.7) 
1 (2.8)
1 (2.8) 
17 (47.2) 
0 (0)
0.603 1.54 (0.30-7.92)
SLCO1B3 rs4149117 
 TT 
 TG 
 GG
1 (2.8) 
9 (25) 
8 (22.2)
1 (2.8) 
5 (13.9) 
12 (33.3)
0.389 1 (0.24-4.16)
SLCO1B3 rs7311358 
 GG 
 GA 
 AA
1 (2.8)
9 (25) 
8 (22.2)
1 (2.8) 
5 (13.9) 
12 (33.3)
0.389 1 (0.24-4.16)
Haplotype 
 c*1a (388A521T) 
 Other *1a 
 d*1b (388G521T) 
 Other *1b 
 e*5 (388A521C) 
 Other *5
5 
13 
17 
1 
5 
13
4 
14 
18 
0 
3 
15
1 
1 
0.691
0.85 (0.38-1.93) 
-
0.7 (0.27-1.82)
Haplotype groups 
 -/-f 
 *15/-g
11 
7
2 
16
0.005 4.52 (1.22-16.64)
aData are calculated using Fisher’s exact test, bRisk ratio (Confidence Interval), c*1a including (*1a/*1a, *1a/*1b, 
*1a/*15), d*1b including (*1b/*1b, *1a/*1b, *1b/*5, *1b/*15), e*5 including (*1b/*5, *1a/*5, *5/*5, *5/*15), f-/- 
including (*1a/*1a, *1a/*1b, *1b/*1b), g*15/- indicates at least one *15 allele (*1b/*15, *1a/*15, *5/*15, *15/*15).
DISCUSSION
Our study is the first in an Indonesian 
population to demonstrate that the 
SLCO1B1*15 haplotype can be associated 
with clinical outcome in patients with PTB 
and EPTB. Among the TB patients with lower 
RIF concentrations,20 we found this haplotype 
in 63.9%, which is consistent with other 
studies of Indonesian patients.7 The lower 
RIF concentrations observed for Indonesians 
could be partially accounted for by the 
SLCO1B1*15 haplotype. The high frequency 
of the SLCO1B1*15 haplotype suggests that 
the haplotype can help to predict the clinical 
outcome for certain Indonesian populations. 
We investigated the effect of major haplotypes 
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of drug transporters and related demographics 
on clinical outcome. We analyzed factors 
that could influence outcome of treatment 
in Indonesian PTB and EPTB patients. The 
variable - SLCO1B1*15 haplotype -was found 
to significantly affect the clinical outcome. 
We identified a significant link between 
SLCO1B1*15 haplotype and treatment,21-23 
which could be explained by decreased 
hepatocellular uptake due to reduced drug 
transporter activity mediated by OATP1B1.24
Some studies examining both peak plasma 
concentration (Cmax) and area under the curve 
(AUC) of RIF exposure have demonstrated 
definite correlation with clinical outcomes.25,26 
Related to genetic diversity, advances in 
genotyping of SLCO1B1 rs11045818 have 
identified a synonymous variant (411G>A) 
(https://www.ncbi.nlm.nih.gov/clinvar/ 
variation/307936/). For SLCO1B3, we did 
not observe any significant pharmacogenetic 
effects due to its limited impact. Our 
findings confirmed there is some effect of the 
SLCO1B1*15 haplotype on RIF exposure 
and treatment outcome, but presently it is 
not well understood. Although c.521T>C and 
c.388A>G SNPs appear to be insignificant, 
the SLCO1B1*15 haplotype (which includes 
both SNPs) has been consistently associated 
with reduced OATP1B1 transport activity.21 
There were also some limitations in our 
study. For example, all of our investigated 
patients were coadministered isoniazid, 
ethambutol and pyrazinamide with RIF, and 
thus any confounding effects of medicines 
could not be fully eliminated in this study. 
Nonetheless, the present results indicate that 
OATP1B1 variants may be involved in the 
failure of clinical outcome and provide a new 
potential failure risk for patients with this 
disease.
CONCLUSION
Our final results show the SLCO1B1*15 
haplotype exists in the Indonesian population 
and is associated with the effect of reducing 
the clinical outcome. This link was examined 
in an Indonesian population with PTB and 
EPTB. Because of high frequency of the 
SLCO1B1*15 haplotype compared to non-
*15 haplotype, our data suggests that this 
genotype may provide some prediction for 
clinical outcome and therefore, specialized 
diagnosis and treatment should be considered 
for select Indonesian patients discriminatively 
based on individual genetic assessment. 
Actual clinical studies are needed to evaluate 
and confirm the variability of genotypes for 
the general population.
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